Roger J. Smith

Roger J. Smith

Auto-generated profile, based on publicly available information

Roger J. Smith

Department of Critical Care Medicine, St Vincent’s Hospital Melbourne, Fitzroy VIC, Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2018 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
RSRoger J. Smith
Roger J. Smith
DRDavid A. Reid
David A. Reid
JSJohn D. Santamaria
John D. Santamaria

1 August 2015 in Journal of Critical Care
Verified
Journal Article
Closed access
RSRoger J. Smith
Roger J. Smith
JSJohn D. Santamaria
John D. Santamaria
EFEspedito E. Faraone
Espedito E. Faraone
JHJennifer A. Holmes
Jennifer A. Holmes
DRDavid A. Reid
David A. Reid
ATAntony E. Tobin
Antony E. Tobin

1 March 2017 in Critical Care and Resuscitation
Verified
Journal Article
Open access
RSRoger J. Smith
Roger J. Smith
JSJohn D. Santamaria
John D. Santamaria
EFEspedito E. Faraone
Espedito E. Faraone
JHJennifer A. Holmes
Jennifer A. Holmes
DRDavid A. Reid
David A. Reid
Objectives: To describe the frequency and hospital mortality of problems (diagnoses) encountered by a rapid response team (RRT), and to identify the most common diagnoses for RRT triggers and for treating units. Design: For each RRT event in 2015 at a tertiary hospital for adults, we chose the diagnosis that best explained the RRT event from a pre-defined list after reviewing relevant test results and clinical notes. Results: There were 937 RRT events during 700 admissions and there were 58 different RRT diagnoses in 11 diagnosis groups. The largest groups were neurological and consciousness problems (22.9%), circulatory problems (19.0%) and breathing problems (16.0%). The most common diagnoses were rapid atrial fibrillation (7.6%) and oversedation or narcosis (4.8%). When SpO2 < 90% triggered RRT review, the leading diagnoses were complex respiratory failure (25.9%) and pneumonia (11.4%). When decreased conscious state triggered review, the main problems were neurological, but there were 39 different diagnoses among these cases. The main problems among orthopaedic cases were post-operative hypovolaemia (19.0%) and spinal anaesthetic-related or epidural analgesic-related hypotension (15.2%). Hospital mortality was 101/700 (14.4%). Diagnoses with high mortality included gastrointestinal bleeding (4/17, 23.5%), complex respiratory failure (8/33, 24.2%), intracranial event (8/28, 28.6%), cardiogenic shock or acute heart failure (5/17, 29.4%), pneumonia (7/21, 33.3%), chest sepsis (5/11, 45.5%) and cardiac arrest (18/26, 69.2%). Conclusions: The RRT activation trigger provides only a general indication of the diagnosis. Some problems appear preventable and could provide a focus for unit-based quality initiatives. The mortality of some diagnoses is substantial, and this may help in setting treatment goals, but more work is needed to understand the association of RRT diagnosis and outcome.

4 July 2017 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
RSRoger J. Smith
Roger J. Smith
JSJohn D. Santamaria
John D. Santamaria
JHJennifer A. Holmes
Jennifer A. Holmes
EFEspedito E. Faraone
Espedito E. Faraone
PHPatricia N. Hurune
Patricia N. Hurune
DRDavid A. Reid
David A. Reid


27 March 2025 in Anaesthesia and Intensive Care
Verified
Journal Article
Closed access
RSRoger J Smith
Roger J Smith
AGAngajendra N Ghosh
Angajendra N Ghosh
SSSimone Said
Simone Said
FHFrank Mp van Haren
Frank Mp van Haren
JLJohn G Laffey
John G Laffey
BDBarry Dixon
Barry Dixon
Nebulised unfractionated heparin (UFH) might reduce time to ventilator separation in patients with COVID-19 by reducing virus infectivity, pulmonary coagulopathy, and inflammation, but clinical trial data are limited. Between 1 July 2020 and 23 March 2022, we conducted, at two hospitals in Victoria, Australia, a randomised, parallel-group, open-label, controlled trial of nebulised UFH. Eligible patients were aged 18 years or more, intubated, under intensive care unit management, had a P a O 2 to F I O 2 ratio of 300 or less, had acute opacities affecting at least one lung quadrant and attributed to COVID-19, and were polymerase chain reaction-positive for SARS-CoV-2 or had further testing planned. The target sample size was 270, however, the trial was stopped due to slow recruitment. There were 50 enrolments, all of whom were analysed. The median age was 55 (interquartile range (IQR) 46–64) years, 28 (56%) were males, and 46 (92%) had acute respiratory distress syndrome. Twenty-seven (54%) were randomised to nebulised heparin and 23 (46%) to standard care. Nebulised UFH was administered to the heparin group on 6 (IQR 4–10) days; median daily dose of 83 (IQR 75–88) kIU. The primary outcome, time to separation from invasive ventilation to day 28 adjusted for the competing risk of death, was not significantly different between groups but took numerically longer in the nebulised heparin group (12.0, standard deviation (SD) 10.4 days versus 7.4, SD 6.9 days; hazard ratio (HR) 0.56, 95% confidence interval (CI) 0.31 to 1.01, P = 0.052). One patient died by day 28 in each group, fewer than expected. Time to separation from invasive ventilation among survivors to day 28 occurred more quickly than expected in the standard care group and was, without correction for multiple comparisons, significantly slower in the heparin group (11.3, SD 10.0 days, n = 26 versus 6.4, SD 5.2 days, n = 22; HR 0.52, 95% CI 0.30 to 0.92, P = 0.024). Nebulised heparin did not reduce time to ventilator separation in intubated adult patients with COVID-19. The study is limited by the small sample size and potential for sampling bias. Further study is required.